ECSP22010042A - Sistema de administración de medicamentos para la administración de agentes antivíricos - Google Patents

Sistema de administración de medicamentos para la administración de agentes antivíricos

Info

Publication number
ECSP22010042A
ECSP22010042A ECSENADI202210042A ECDI202210042A ECSP22010042A EC SP22010042 A ECSP22010042 A EC SP22010042A EC SENADI202210042 A ECSENADI202210042 A EC SENADI202210042A EC DI202210042 A ECDI202210042 A EC DI202210042A EC SP22010042 A ECSP22010042 A EC SP22010042A
Authority
EC
Ecuador
Prior art keywords
administration
drug delivery
delivery system
antiviral agents
hiv
Prior art date
Application number
ECSENADI202210042A
Other languages
English (en)
Inventor
Anthanas Koynov
Morgan B Giles
Stephanie Elizabeth Barrett
Seth P Forster
Ryan S Teller
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of ECSP22010042A publication Critical patent/ECSP22010042A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0092—Hollow drug-filled fibres, tubes of the core-shell type, coated fibres, coated rods, microtubules or nanotubes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Nanotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)

Abstract

Esta invención se refiere a novedosos sistemas de administración de fármacos por implante para la administración de fármacos antivíricos de acción prolongada. Estas composiciones son útiles para el tratamiento o la prevención de la infección por el virus de la inmunodeficiencia humana (VIH).
ECSENADI202210042A 2019-08-13 2022-02-08 Sistema de administración de medicamentos para la administración de agentes antivíricos ECSP22010042A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962885968P 2019-08-13 2019-08-13

Publications (1)

Publication Number Publication Date
ECSP22010042A true ECSP22010042A (es) 2022-03-31

Family

ID=74570758

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202210042A ECSP22010042A (es) 2019-08-13 2022-02-08 Sistema de administración de medicamentos para la administración de agentes antivíricos

Country Status (18)

Country Link
US (1) US20220362277A1 (es)
EP (1) EP4013407A4 (es)
JP (1) JP7317210B2 (es)
KR (1) KR20220047307A (es)
CN (1) CN114206336A (es)
AU (1) AU2020328518A1 (es)
BR (1) BR112022002386A2 (es)
CA (1) CA3150272A1 (es)
CL (1) CL2022000318A1 (es)
CO (1) CO2022001356A2 (es)
CR (1) CR20220053A (es)
DO (1) DOP2022000036A (es)
EC (1) ECSP22010042A (es)
IL (1) IL290421A (es)
JO (1) JOP20220033A1 (es)
MX (1) MX2022001765A (es)
PE (1) PE20220707A1 (es)
WO (1) WO2021030306A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20170038B1 (ar) * 2016-02-12 2021-08-17 Merck Sharp & Dohme مركبات للاستخدام لعلاج عدوى بفيروس hiv والوقاية منه

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05012768A (es) * 2003-05-30 2006-02-22 Titan Pharmaceuticals Inc Dispositivo polimerico implantable para liberacion prolongada de nalmefeno.
CA2502109C (en) * 2004-03-24 2010-02-23 Yamasa Corporation 4'-c-substituted-2-haloadenosine derivative
RU2755130C2 (ru) * 2016-05-12 2021-09-13 Мерк Шарп И Доум Корп. Система доставки лекарств для доставки противовирусных средств
US11419817B2 (en) * 2017-04-10 2022-08-23 Merck Sharp & Dohme Llc Drug delivery system for the delivery of antiviral agents
KR20210105931A (ko) * 2018-12-20 2021-08-27 머크 샤프 앤드 돔 코포레이션 Nrtti 화합물의 신규 결정질 형태

Also Published As

Publication number Publication date
EP4013407A4 (en) 2023-08-23
CR20220053A (es) 2022-04-20
BR112022002386A2 (pt) 2022-04-26
PE20220707A1 (es) 2022-05-04
MX2022001765A (es) 2022-03-17
CL2022000318A1 (es) 2022-10-07
JOP20220033A1 (ar) 2023-01-30
CN114206336A (zh) 2022-03-18
EP4013407A1 (en) 2022-06-22
CA3150272A1 (en) 2021-02-18
AU2020328518A1 (en) 2022-03-10
CO2022001356A2 (es) 2022-03-18
DOP2022000036A (es) 2022-03-31
IL290421A (en) 2022-04-01
JP2022546755A (ja) 2022-11-08
JP7317210B2 (ja) 2023-07-28
WO2021030306A1 (en) 2021-02-18
KR20220047307A (ko) 2022-04-15
US20220362277A1 (en) 2022-11-17

Similar Documents

Publication Publication Date Title
MX2018013662A (es) Sistema de entrega de farmacos para la entrega de agentes antivirales.
EA202192099A2 (ru) Системы доставки с замедленным высвобождением, содержащие бесследные линкеры
CO2018010026A2 (es) Profármacos de fármacos citotóxicos que tienen grupos enzimáticamente escindibles
CO2022014073A2 (es) Compuestos antivirales y métodos para la administración de los mismos
CL2019003309A1 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue.
CU20110208A7 (es) Derivados de la piridina de tieno (2,3-b) como inhibidores virales de la réplica
CU20170109A7 (es) Derivado de quinoleina para tratar y prevenir infecciones virales
CO2019010295A2 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
NZ741957A (en) Therapeutic compositions for treatment of human immunodeficiency virus
BR112022004424A2 (pt) Pró-fármacos antivirais e formulações dos mesmos
CO2019012035A2 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
CL2017000714A1 (es) Composiciones farmacéuticas de acción prolongada
SA520410975B1 (ar) تركيبات طويلة المفعول
DOP2022000036A (es) Sistema de administración de medicamentos para la administración de agentes antivíricos
UY38625A (es) Compuestos y su uso en el tratamiento del cáncer
CL2023001894A1 (es) Análogos de rifamicina y conjugados de fármaco-anticuerpo de los mismos
CO2021017479A2 (es) Derivados de pirido [2,3-d] pirimidina como inhibidores de la replicación del virus de inmunodeficiencia humana
DOP2022000171A (es) Compuestos tetracíclicos para el tratamiento de infecciones por vih
BRPI0820343A2 (pt) Anticorpos de antifator b e seus usos
BR112022010574A2 (pt) Composições farmacêuticas compreendendo cabotegravir
BR112022021834A2 (pt) Sistema de fornecimento de fármaco por implante, e, método para tratar ou prevenir infecção pelo vírus da imunodeficiência humana e prevenir gravidez
BR112022008039A2 (pt) Compostos de 4-amino-imidazoquinolina e usos relacionados
BR112017019205A2 (pt) agente de tratamento de infecção respiratória
WO2018067663A3 (en) Ketolides having antibacterial activity
EA202191739A1 (ru) Аналоги рифамицина и конъюгаты антитело-лекарственное средство с ними